Not Signed In - Sirion Therapeutics Initiates Enrollment Of Phase II Clinical Trial For The Treatment Of Geographic Atrophy
Tue, 05 Dec 2006 08:00 AM EST
... Sirion Therapeutics, Inc., an ophthalmic-focused biopharmaceuticals company, announced today that it has begun enrollment of a phase II clinical trial, which will evaluate fenretinide in the treatment of Geographic Atrophy (GA) in patients with age-related macular degeneration. [click link for full article] ...
Related Topics
- Clinical Trials
- Pharmacology
- Spinal Muscular Atrophy
- Cerebral Atrophy
- Pancreatic Cancer
- Trastuzumab
- Psychopharmacology
- Spinal and bulbar muscular atrophy
- Crohn's Disease
- Urogenital Atrophy
- Tarceva
- Multiple System Atrophy
- Geographic tongue
- Nystatin and Triamcinolone
- Distal spinal muscular atrophy, type V
- Western/Clinical Treatment and Therapy
- Depression
- Food Recommendations: South Beach Diet - Phase 2
- Food Recommendations: South Beach Diet - Phase 1
- Juvenile Diabetes
email this page
print this page
bookmark this page
feedback on this page
